Marburg virus: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 25: | Line 25: | ||
*Mortality 23 to 90% |
*Mortality 23 to 90% |
||
| − | == |
+ | ==Diagnosis== |
| − | * |
+ | *RT-PCR at the National Microbiology Laboratory |
| − | ** |
+ | **Inform microbiology lab beforehand and contact Public Health for collection instructions |
==Management== |
==Management== |
||
| Line 35: | Line 35: | ||
*Experimental therapies include [[favipiravir]] and monoclonal antibodies |
*Experimental therapies include [[favipiravir]] and monoclonal antibodies |
||
| − | == |
+ | ==Prevention== |
| + | |||
| + | ===Vaccination=== |
||
*Vaccination is under investigation |
*Vaccination is under investigation |
||
| + | |||
| + | ===Infection Prevention and Control=== |
||
| + | |||
| + | *Isolate patient |
||
| + | *Droplet precautions and face protection within 1 meter of patient |
||
| + | *Limit hospital staff who have contact |
||
[[Category:Filoviridae]] |
[[Category:Filoviridae]] |
||
Latest revision as of 09:41, 28 August 2020
Background
Microbiology
- Negative-sense single-stranded RNA virus in the Filoviridae family
- Genus contains two species
- Marburg virus
- Ravn virus
Epidemiology
- Rare, with 11 outbreaks since discovery in 1967, totalling 470 cases
- Animal reservoir is fruit bat, with a sylvian cycle that occasionally spills over into human populations
- The range of the reservoir extends into Middle East, South Asia, and south Pacific, but the virus is essentially limited to subsaharan Africa
Clinical Manifestations
- Incubation period 2 to 21 days
- Starts with high fever, severe headache malaise
- Followed by multi-system involvement as early as day 3
- Nausea, vomiting, anorexia, abdominal pain, diarrhea (can persist for a week)
- Chest pain, dyspnea, cough
- Hypotension, edema, maculopapular rash
- Headache, confusion
- Mortality 23 to 90%
Diagnosis
- RT-PCR at the National Microbiology Laboratory
- Inform microbiology lab beforehand and contact Public Health for collection instructions
Management
- Good supportive care decreases mortality substantially
- Experimental therapies include favipiravir and monoclonal antibodies
Prevention
Vaccination
- Vaccination is under investigation
Infection Prevention and Control
- Isolate patient
- Droplet precautions and face protection within 1 meter of patient
- Limit hospital staff who have contact
